Evidence map›Paper›PMID 32727534›Full record

ArticleBMC molecular and cell biology2020

An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model.

Jing Ai, Jian Ma, Zhi-Qing Chen, Jun-Hui Sun, Ke Yao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC molecular and cell biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Systemic Cytokines in Retinopathy of Prematurity.Journal of personalized medicine · 2023
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jing AiEye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang Province, China.
Jian MaEye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang Province, China.
Zhi-Qing ChenEye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang Province, China.
Jun-Hui SunHepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang Province, China. 1307005@zju.edu.cn.
Ke YaoEye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang Province, China. xlren@zju.edu.cn.
Second Affiliated Hospital of Zhejiang University · CNFirst Affiliated Hospital Zhejiang University · CN

Funding

National Natural Science Foundation of China 81570822National Natural Science Foundation of China 81571819National Natural Science Foundation of China 81971713National S&T Major Project of China NO.SQ2018ZX100301Natural Science Foundation of Zhejiang Province LY16H120002Natural Science Foundation of Zhejiang Province LZ18H180001Zhejiang Key Laboratory Fund of China 2011E10006Zhejiang Province Key Research and Development Program 2015C03042
6 · The paper itself

Abstract

backgroundTransplantation of gene transfected endothelial progenitor cells (EPCs) has provided novel methods for tumor neovascularization therapy but not for ocular disease therapy. This study aimed to investigate the efficacy of endostatin transfected EPCs in retinal neovascularization therapy.

resultsQuantitative reverse transcription-polymerase chain reaction (qRT-PCR) showed the high expression of endostatin in endostatin-lentivirus-EPCs. The neovascularization leakage area and the number of preretinal neovascular cell nuclei were significantly decreased in the endostatin-lentivirus and endostatin-lentivirus-EPC groups, and the effects of these two treatments on inhibiting retinal neovascularization were almost the same. These two groups also showed the greater retinal distribution of endostatin. Intravitreal injections of endostatin-lentivirus-EPCs inhibited retinal neovascularization, vascular endothelial growth factor (VEGF) and CD31 expression, and increased endostatin expression in vivo. Endostatin-lentivirus-EPCs targeted and prevented pathologic retinal neovascularization.

conclusionsGene-combined EPCs represent a potential new therapeutic agent for the treatment of neovascular eye diseases.

Indexed as

Genetic TherapyAnimalsDisease Models, AnimalEndostatinsEndothelial Progenitor CellsFluorescein AngiographyFundus OculiLentivirusOxygenPlatelet Endothelial Cell Adhesion Molecule-1Rats, Sprague-DawleyRetinal NeovascularizationRNA, MessengerVascular Endothelial Growth FactorsEndostatinsOxygenPlatelet Endothelial Cell Adhesion Molecule-1RNA, MessengerVascular Endothelial Growth FactorsEndostatinEndothelial progenitor cellsGene therapyRetinal neovascularization

Identifiers

PMID32727534
PMCPMC7392664
OpenAlexW3046083392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.